PDT is particularly suitable for:
Multiple studies confirm the efficacy of vascular-targeted PDT for prostate cancer. A pivotal randomized trial published in The Lancet Oncology (2017) showed that men treated with Padeliporfin-based PDT had significantly lower progression rates compared to those under active surveillance, without the typical side effects of surgery or radiation (Lancet Oncol. 2017;18(2):181–191). The treatment is CE-certified and widely used across Europe.